Rachel Louise Knowles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rachel Louise Knowles has a total of 380 co-authors. Here are the top co-authors by number of shared publications:
Catherine Bull
Department of Cardiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
18 shared publications- Carol Dezateux
Life Course Epidemiology and Biostatistics, UCL Great Ormond Street Institute of Child Health, London, UK
14 shared publications - Katherine Loraine Brown
Great Ormond Street Hospital Biomedical Research Centre, London, UK
14 shared publications Jenifer Tregay
Department of Clinical Psychology, John Radcliffe Hospital, Oxford, Oxfordshire, UK
11 shared publications- Andrew Farmer
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom
9 shared publications - David Moher
Institute of Health Policy, Management & Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
9 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 291, 352-361
Factors Associated With Delays in the Diagnosis of Childhood Onset Uveitis: Findings From a Nation-Wide Cohort Study
- 4 August 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 291, 352-361
Open AccessFactors Associated With Delays in the Diagnosis of Childhood Onset Uveitis: Findings From a Nation-Wide Cohort Study
- Open Access
- 15 July 2026
- Published by Springer Nature in Pediatric Cardiology
Factors Influencing Weight Gain at Different Stages of the Fontan Pathway for Children with Functionally Single Ventricle Heart Disease.
Outcomes for functionally single ventricle heart (f-SV) conditions rely on careful management of staged surgical palliation. Studies report a decrease in weight-for-age z-score (WAZ) before Stage 2 (Glenn) procedure, with weight gain thereafter, however factors influencing WAZ changes remain unclear. Using National Congenital Heart Disease Audit data, we developed regression models to explore WAZ changes from Stage 1 (S1) to Stage 2 (S2), and S2 to Stage 3 (S3), on the single ventricle (Fontan) pathway for 3292 operated f-SV patients born 2000 to 2018 in England and Wales. Mean WAZ decreased from - 1.20 (SD 1.60) at S1 to - 1.47 (SD 1.32) at S2, with recovery to - 0.57 (SD 1.16) by S3 Fontan-type surgery. In a multivariable model including 2012 children surviving to S2, female sex and older age at S1 were associated with increased WAZ from S1 to S2 while non-cardiac anomalies and higher WAZ at S1 were associated with decreasing WAZ. In a second model, including 1244 survivors to S3, weight gain between S2 and S3 was associated with preterm birth and Black ethnicity; whereas female sex, unbalanced AVSD diagnosis, older age or higher WAZ at S2, and greater weight gain between S1 and S2 were associated with WAZ decrease. Analyses confirmed that mean WAZ decreases prior to S2, increases after S2 surgery, and is influenced by age and weight at each procedure. Factors associated with weight gain varied across the single ventricle pathway. Further investigation is needed to understand wider influences on growth, including intensive interstage nutrition.
- 15 July 2026
- Published by Springer Nature in Pediatric Cardiology
Open AccessFactors Influencing Weight Gain at Different Stages of the Fontan Pathway for Children with Functionally Single Ventricle Heart Disease.
Outcomes for functionally single ventricle heart (f-SV) conditions rely on careful management of staged surgical palliation. Studies report a decrease in weight-for-age z-score (WAZ) before Stage 2 (Glenn) procedure, with weight gain thereafter, however factors influencing WAZ changes remain unclear. Using National Congenital Heart Disease Audit data, we developed regression models to explore WAZ changes from Stage 1 (S1) to Stage 2 (S2), and S2 to Stage 3 (S3), on the single ventricle (Fontan) pathway for 3292 operated f-SV patients born 2000 to 2018 in England and Wales. Mean WAZ decreased from - 1.20 (SD 1.60) at S1 to - 1.47 (SD 1.32) at S2, with recovery to - 0.57 (SD 1.16) by S3 Fontan-type surgery. In a multivariable model including 2012 children surviving to S2, female sex and older age at S1 were associated with increased WAZ from S1 to S2 while non-cardiac anomalies and higher WAZ at S1 were associated with decreasing WAZ. In a second model, including 1244 survivors to S3, weight gain between S2 and S3 was associated with preterm birth and Black ethnicity; whereas female sex, unbalanced AVSD diagnosis, older age or higher WAZ at S2, and greater weight gain between S1 and S2 were associated with WAZ decrease. Analyses confirmed that mean WAZ decreases prior to S2, increases after S2 surgery, and is influenced by age and weight at each procedure. Factors associated with weight gain varied across the single ventricle pathway. Further investigation is needed to understand wider influences on growth, including intensive interstage nutrition.
- Open Access
- 28 April 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 195, 112294
Whole population cohorts vs sampled comparators designs for evaluating health and educational outcomes of children with inborn rare conditions: a simulation study
- 28 April 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 195, 112294
Open AccessWhole population cohorts vs sampled comparators designs for evaluating health and educational outcomes of children with inborn rare conditions: a simulation study
- 19 March 2026
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111 (6) , 471-472
Learning from deaths: the enduring value of mortality analysis to paediatric heart disease
- 19 March 2026
- Published by BMJ in Archives of Disease in Childhood
- Vol. 111 (6) , 471-472
Learning from deaths: the enduring value of mortality analysis to paediatric heart disease
- Open Access
- 13 January 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (1) , 3
Newborn Screening for Spinal Muscular Atrophy in the UK: Use of Modelling to Identify Priorities for Ongoing Evaluation
Spinal muscular atrophy (SMA) is a genetic condition that causes the degeneration of motor neurons in the spinal cord. Newborn blood spot (NBS) screening can potentially enable diagnosis before symptoms, and presymptomatic treatment is considered to be more effective than symptomatic treatment. In this paper, we present an overview of a cost-effectiveness model of NBS screening for SMA in the UK, informed by key clinical trials and the relevant published literature. Our analyses suggest that implementing screening could result in better outcomes and lower costs compared to the current approach of no screening plus treatment. However, several uncertainties and limitations of the model remain. These include uncertainty in the reimbursement status of nusinersen and risdiplam in the future; the ‘actual’ costs of treatments, as they are under confidential commercial agreements; uncertainty in the long-term effectiveness of presymptomatic and symptomatic treatment; and uncertainty around the incidence of SMA and the costs and the accuracy of NBS screening. An SMA in-service evaluation (ISE) that could capture data specific to the UK is under consideration, and an appropriately designed ISE with ongoing data collection could support periodic updates of clinical and cost-effectiveness estimates of NBS screening for SMA in the UK.
- 13 January 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (1) , 3
Open AccessNewborn Screening for Spinal Muscular Atrophy in the UK: Use of Modelling to Identify Priorities for Ongoing Evaluation
Spinal muscular atrophy (SMA) is a genetic condition that causes the degeneration of motor neurons in the spinal cord. Newborn blood spot (NBS) screening can potentially enable diagnosis before symptoms, and presymptomatic treatment is considered to be more effective than symptomatic treatment. In this paper, we present an overview of a cost-effectiveness model of NBS screening for SMA in the UK, informed by key clinical trials and the relevant published literature. Our analyses suggest that implementing screening could result in better outcomes and lower costs compared to the current approach of no screening plus treatment. However, several uncertainties and limitations of the model remain. These include uncertainty in the reimbursement status of nusinersen and risdiplam in the future; the ‘actual’ costs of treatments, as they are under confidential commercial agreements; uncertainty in the long-term effectiveness of presymptomatic and symptomatic treatment; and uncertainty around the incidence of SMA and the costs and the accuracy of NBS screening. An SMA in-service evaluation (ISE) that could capture data specific to the UK is under consideration, and an appropriately designed ISE with ongoing data collection could support periodic updates of clinical and cost-effectiveness estimates of NBS screening for SMA in the UK.
- Open Access
Whole population cohorts versus sampled comparators designs for evaluating health and educational outcomes of children with inborn rare conditions: a simulation study
Background Linked administrative data covering whole populations are fundamental resources for longitudinal studies of children with rare conditions (cases) and unaffected peers (comparators). Data minimisation regulations sometimes limit the number of comparators per case (sampled comparators, SC), with unknown impact on study findings. Methods Using Monte Carlo draws, we simulated 100 000 children with and without an exemplar condition, congenital hypothyroidism (CHT), with covariates (sex and comorbidity). Three outcomes (Y: Maths tests z-score, age 11 years; L: achieving expected Maths attainment (binary); T: months to neurodevelopmental disorder diagnosis) were modelled as linear combinations of CHT, sex and comorbidity. Varying parameters (comorbidity prevalence; comorbidity-CHT association; CHT effect on Y/L/T) factorially produced 36 data-generating mechanisms (DGMs). We used regression coefficients (CHT effect), standard errors (SEs) and p-values from 1000 simulations to evaluate power, precision and bias, comparing SCn (n=5/10/15/25/50/100) versus full cohort (FC). Results Mean p-values and SEs for SC25 generally deviated ≤5% versus FC with medium effects (z-score difference=0.3; odds/hazard ratios≥2), and ≤2% for large effects (z-score difference≥0.6; odds/hazard ratios≥5). For all outcomes, no SC nor FC had sufficient power (>80% of p-values≤0.05) with small or medium effects, whilst all SC had sufficient power with large effects. Compared with FC, precision loss for SC25 was 2.0-4.3%, 5.0-8.9%, 6.7-15.5% for Y, L, T respectively. SC was not associated with bias. Conclusion SC25 provided comparable performance as FC for rare disease studies under several scenarios, but small effects posed challenges, notwithstanding sampling. This approach generates cost-effective recommendations for study design and data minimisation.
Open AccessWhole population cohorts versus sampled comparators designs for evaluating health and educational outcomes of children with inborn rare conditions: a simulation study
Background Linked administrative data covering whole populations are fundamental resources for longitudinal studies of children with rare conditions (cases) and unaffected peers (comparators). Data minimisation regulations sometimes limit the number of comparators per case (sampled comparators, SC), with unknown impact on study findings. Methods Using Monte Carlo draws, we simulated 100 000 children with and without an exemplar condition, congenital hypothyroidism (CHT), with covariates (sex and comorbidity). Three outcomes (Y: Maths tests z-score, age 11 years; L: achieving expected Maths attainment (binary); T: months to neurodevelopmental disorder diagnosis) were modelled as linear combinations of CHT, sex and comorbidity. Varying parameters (comorbidity prevalence; comorbidity-CHT association; CHT effect on Y/L/T) factorially produced 36 data-generating mechanisms (DGMs). We used regression coefficients (CHT effect), standard errors (SEs) and p-values from 1000 simulations to evaluate power, precision and bias, comparing SCn (n=5/10/15/25/50/100) versus full cohort (FC). Results Mean p-values and SEs for SC25 generally deviated ≤5% versus FC with medium effects (z-score difference=0.3; odds/hazard ratios≥2), and ≤2% for large effects (z-score difference≥0.6; odds/hazard ratios≥5). For all outcomes, no SC nor FC had sufficient power (>80% of p-values≤0.05) with small or medium effects, whilst all SC had sufficient power with large effects. Compared with FC, precision loss for SC25 was 2.0-4.3%, 5.0-8.9%, 6.7-15.5% for Y, L, T respectively. SC was not associated with bias. Conclusion SC25 provided comparable performance as FC for rare disease studies under several scenarios, but small effects posed challenges, notwithstanding sampling. This approach generates cost-effective recommendations for study design and data minimisation.
- Open Access
- 31 July 2025
- Published by The Ewha Medical Journal, Ewha Womans University College of Medicine in Ewha Medical Journal
- Vol. 48 (3) , e50
CONSORT 2025 statement: updated guideline for reporting randomized trials: a Korean translation
CONSORT 2025 statement: updated guideline for reporting randomized trials: a Korean translation
- 31 July 2025
- Published by The Ewha Medical Journal, Ewha Womans University College of Medicine in Ewha Medical Journal
- Vol. 48 (3) , e50
Open AccessCONSORT 2025 statement: updated guideline for reporting randomized trials: a Korean translation
CONSORT 2025 statement: updated guideline for reporting randomized trials: a Korean translation
- Top Cited PapersOpen Access
- 29 April 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (6) , 1784-1792
SPIRIT 2025 statement: updated guideline for protocols of randomized trials
The protocol of a randomized trial is the foundation for study planning, conduct, reporting and external review. However, trial protocols vary in their completeness and often do not address key elements of design and conduct. The SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement was first published in 2013 as guidance to improve the completeness of trial protocols. Periodic updates incorporating the latest evidence and best practices are needed to ensure that the guidance remains relevant to users. Here, we aimed to systematically update the SPIRIT recommendations for minimum items to address in the protocol of a randomized trial. We completed a scoping review and developed a project-specific database of empirical and theoretical evidence to generate a list of potential changes to the SPIRIT 2013 checklist. The list was enriched with recommendations provided by lead authors of existing SPIRIT/CONSORT (Consolidated Standards of Reporting Trials) extensions (Harms, Outcomes, Non-pharmacological Treatment) and other reporting guidelines (TIDieR). The potential modifications were rated in a three-round Delphi survey followed by a consensus meeting. Overall, 317 individuals participated in the Delphi consensus process and 30 experts attended the consensus meeting. The process led to the addition of two new protocol items, revision to five items, deletion/merger of five items, and integration of key items from other relevant reporting guidelines. Notable changes include a new open science section, additional emphasis on the assessment of harms and description of interventions and comparators, and a new item on how patients and the public will be involved in trial design, conduct and reporting. The updated SPIRIT 2025 statement consists of an evidence-based checklist of 34 minimum items to address in a trial protocol, along with a diagram illustrating the schedule of enrollment, interventions and assessments for trial participants. To facilitate implementation, we also developed an expanded version of the SPIRIT 2025 checklist and an accompanying explanation and elaboration document. Widespread endorsement and adherence to the updated SPIRIT 2025 statement have the potential to enhance the transparency and completeness of trial protocols for the benefit of investigators, trial participants, patients, funders, research ethics committees, journals, trial registries, policymakers, regulators and other reviewers.
- 29 April 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (6) , 1784-1792
Top Cited PapersOpen AccessSPIRIT 2025 statement: updated guideline for protocols of randomized trials
The protocol of a randomized trial is the foundation for study planning, conduct, reporting and external review. However, trial protocols vary in their completeness and often do not address key elements of design and conduct. The SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement was first published in 2013 as guidance to improve the completeness of trial protocols. Periodic updates incorporating the latest evidence and best practices are needed to ensure that the guidance remains relevant to users. Here, we aimed to systematically update the SPIRIT recommendations for minimum items to address in the protocol of a randomized trial. We completed a scoping review and developed a project-specific database of empirical and theoretical evidence to generate a list of potential changes to the SPIRIT 2013 checklist. The list was enriched with recommendations provided by lead authors of existing SPIRIT/CONSORT (Consolidated Standards of Reporting Trials) extensions (Harms, Outcomes, Non-pharmacological Treatment) and other reporting guidelines (TIDieR). The potential modifications were rated in a three-round Delphi survey followed by a consensus meeting. Overall, 317 individuals participated in the Delphi consensus process and 30 experts attended the consensus meeting. The process led to the addition of two new protocol items, revision to five items, deletion/merger of five items, and integration of key items from other relevant reporting guidelines. Notable changes include a new open science section, additional emphasis on the assessment of harms and description of interventions and comparators, and a new item on how patients and the public will be involved in trial design, conduct and reporting. The updated SPIRIT 2025 statement consists of an evidence-based checklist of 34 minimum items to address in a trial protocol, along with a diagram illustrating the schedule of enrollment, interventions and assessments for trial participants. To facilitate implementation, we also developed an expanded version of the SPIRIT 2025 checklist and an accompanying explanation and elaboration document. Widespread endorsement and adherence to the updated SPIRIT 2025 statement have the potential to enhance the transparency and completeness of trial protocols for the benefit of investigators, trial participants, patients, funders, research ethics committees, journals, trial registries, policymakers, regulators and other reviewers.
- Top Cited PapersOpen Access
SPIRIT 2025 statement: updated guideline for protocols of randomised trials
Importance The protocol of a randomised trial is the foundation for study planning, conduct, reporting, and external review. However, trial protocols vary in their completeness and often do not address key elements of design and conduct. The SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement was first published in 2013 as guidance to improve the completeness of trial protocols. Periodic updates incorporating the latest evidence and best practices are needed to ensure that the guidance remains relevant to users. Objective To systematically update the SPIRIT recommendations for minimum items to address in the protocol of a randomised trial. Design We completed a scoping review and developed a project specific database of empirical and theoretical evidence to generate a list of potential changes to the SPIRIT 2013 checklist. The list was enriched with recommendations provided by lead authors of existing SPIRIT/CONSORT (Consolidated Standards of Reporting Trials) extensions (Harms, Outcomes, Non-pharmacological Treatment) and other reporting guidelines (TIDieR). The potential modifications were rated in a three-round Delphi survey followed by a consensus meeting. Findings Overall, 317 individuals participated in the Delphi consensus process and 30 experts attended the consensus meeting. The process led to the addition of two new protocol items, revision to five items, deletion/merger of five items, and integration of key items from other relevant reporting guidelines. Notable changes include a new open science section, additional emphasis on the assessment of harms and description of interventions and comparators, and a new item on how patients and the public will be involved in trial design, conduct, and reporting. The updated SPIRIT 2025 statement consists of an evidence based checklist of 34 minimum items to address in a trial protocol, along with a diagram illustrating the schedule of enrolment, interventions, and assessments for trial participants. To facilitate implementation, we also developed an expanded version of the SPIRIT 2025 checklist and an accompanying explanation and elaboration document. Conclusions and relevance Widespread endorsement and adherence to the updated SPIRIT 2025 statement have the potential to enhance the transparency and completeness of trial protocols for the benefit of investigators, trial participants, patients, funders, research ethics committees, journals, trial registries, policymakers, regulators, and other reviewers.
Top Cited PapersOpen AccessSPIRIT 2025 statement: updated guideline for protocols of randomised trials
Importance The protocol of a randomised trial is the foundation for study planning, conduct, reporting, and external review. However, trial protocols vary in their completeness and often do not address key elements of design and conduct. The SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement was first published in 2013 as guidance to improve the completeness of trial protocols. Periodic updates incorporating the latest evidence and best practices are needed to ensure that the guidance remains relevant to users. Objective To systematically update the SPIRIT recommendations for minimum items to address in the protocol of a randomised trial. Design We completed a scoping review and developed a project specific database of empirical and theoretical evidence to generate a list of potential changes to the SPIRIT 2013 checklist. The list was enriched with recommendations provided by lead authors of existing SPIRIT/CONSORT (Consolidated Standards of Reporting Trials) extensions (Harms, Outcomes, Non-pharmacological Treatment) and other reporting guidelines (TIDieR). The potential modifications were rated in a three-round Delphi survey followed by a consensus meeting. Findings Overall, 317 individuals participated in the Delphi consensus process and 30 experts attended the consensus meeting. The process led to the addition of two new protocol items, revision to five items, deletion/merger of five items, and integration of key items from other relevant reporting guidelines. Notable changes include a new open science section, additional emphasis on the assessment of harms and description of interventions and comparators, and a new item on how patients and the public will be involved in trial design, conduct, and reporting. The updated SPIRIT 2025 statement consists of an evidence based checklist of 34 minimum items to address in a trial protocol, along with a diagram illustrating the schedule of enrolment, interventions, and assessments for trial participants. To facilitate implementation, we also developed an expanded version of the SPIRIT 2025 checklist and an accompanying explanation and elaboration document. Conclusions and relevance Widespread endorsement and adherence to the updated SPIRIT 2025 statement have the potential to enhance the transparency and completeness of trial protocols for the benefit of investigators, trial participants, patients, funders, research ethics committees, journals, trial registries, policymakers, regulators, and other reviewers.
- Top Cited PapersOpen Access
SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials
High quality protocols facilitate proper planning, conduct, reporting, and external review of randomised trials, yet their completeness varies and key elements are often not considered. To strengthen good reporting of trial protocols, the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 statement has been updated to incorporate new evidence and emerging perspectives. This SPIRIT 2025 explanation and elaboration document provides users with exemplars of reporting in contemporary trial protocols, contextual elaboration, more detailed guidance on reporting, references to key empirical studies, an expanded checklist, and a link to a website for further information. The document is intended to be used in conjunction with the SPIRIT 2025 statement and serves as a resource for researchers planning a trial and for others interested in trial protocols.
Top Cited PapersOpen AccessSPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials
High quality protocols facilitate proper planning, conduct, reporting, and external review of randomised trials, yet their completeness varies and key elements are often not considered. To strengthen good reporting of trial protocols, the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 statement has been updated to incorporate new evidence and emerging perspectives. This SPIRIT 2025 explanation and elaboration document provides users with exemplars of reporting in contemporary trial protocols, contextual elaboration, more detailed guidance on reporting, references to key empirical studies, an expanded checklist, and a link to a website for further information. The document is intended to be used in conjunction with the SPIRIT 2025 statement and serves as a resource for researchers planning a trial and for others interested in trial protocols.